Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: January 17, 2018, 5-9PM
Minutes prepared by: Nina Bandali and Dave Hoang
Location: Elmer Andersen Building, Room 2340, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., Ph.D., Kyle Lehenbauer, M.D., Eric Meininger, M.D., Kelly Ruby, Pharm.D., Michael Sprehe, M.D., Stuart Williams, J.D., Kathryn Lombardo, M.D.,
- Members absent: Monica Brands, RPh., Stacey Ness, Pharm.D., James Phillips, M.D., Al Heaton, Pharm.D.
- DHS staff present: Chad Hope, Pharm.D., Dave Hoang, Pharm.D., MBA, Mary Beth Reinke, Pharm.D., MSA, Viki Ding, Pharmacy Student
- Others in attendance (via phone): Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair

Mr. Williams presided over the meeting in Dr. Ness’ absence.

Approval of Minutes

Minutes from the October 2017 meeting were reviewed and approved.

Update of Synagis 2017-2018 Season

- The Department informed the DFC that there are no changes to the Synagis prior authorization as there have been no changes in the recommendations by the AAP. The Department adjusts the policy accordingly as per virology reports.

New Drugs for Continued PA

- The committee discussed Armonair Respiclick and recommended to the department by a unanimous vote that Armonair Respiclick remain on PA. The committee also recommended by a unanimous vote that the department manages the category based on cost and availability.
- The committee discussed Trelegy Ellipta and recommended to the department by a unanimous vote that Trelegy Ellipta remain on PA.
Existing Specialty Drugs for Continued PA

- The committee discussed Ruconest and recommended to the department by a unanimous vote that Ruconest remain on PA.

New Specialty Drugs for Continued PA

- The committee discussed Nerlynx and recommended to the department by a unanimous vote that Nerlynx remain on PA.
- The committee discussed Radicava and recommended to the department by a majority vote (1 member abstains) that Radicava remain on PA with the deletion of the requirement that the duration of ALS disease be 2 years or less.
- The committee discussed Triptodur and recommended to the department by a majority vote (1 member abstains) that Triptodur remain on PA.
- The committee discussed Verzenio and recommended to the department by a unanimous vote that Verzenio remain on PA.
- The committee discussed Symproic and recommended to the department by a unanimous vote that Symproic remain on PA with a change to the length of opioid use from 150 out of 180 days to 75 out of 90 days.
- The committee discussed Fiasp/Fiasp FlexTouch and recommended to the department by a unanimous vote that Fiasp/Fiasp FlexTouch remain on PA with the removal of “but has had a demonstrated adequate response to the non-preferred insulin.”
- The committee discussed Parsabiv and recommended to the department by a unanimous vote that Parsabiv remain on PA with a modification to the renewal criteria to add the following after “>30% reduction in baseline mean iPTH”: “or based on meeting identified and targeted goal.”

Adjournment

- This is Dr. Meininger’s last meeting. DHS staff recognizes Dr. Meininger for his advocacy work on behalf of LGBTQ kids.
- The meeting was adjourned at 7:59 PM Central Time